Certainty index
Low certainty — page 2
Confidence in the effect estimate is limited. The true effect may be substantially different from the estimate.
Graded outcomes
52 documents · page 2 of 2
Table 1. Outcomes and syntheses graded at low certainty, on this page.
| Document | Type | Effect or conclusion as recorded |
|---|---|---|
| Thymosin beta-4 in cutaneous wound healing and tissue repair: effect on the anchor outcome | Synthesis | Low certainty evidence from 3 contributing trials bears on the effect of Thymosin beta-4 on the anchor outcome for cutaneous wound healing and tissue repair. The estimate the Institute carries in the… |
| CJC-1295 in growth hormone deficiency and growth-hormone secretagogue pharmacology: effect on the anchor… | Synthesis | Low certainty evidence from 2 contributing trials bears on the effect of CJC-1295 on the anchor outcome for growth hormone deficiency and growth-hormone secretagogue pharmacology. The estimate the… |
| GHK-Cu in cutaneous wound healing and tissue repair: effect on the anchor outcome | Synthesis | Low certainty evidence from 2 contributing trials bears on the effect of GHK-Cu on the anchor outcome for cutaneous wound healing and tissue repair. The estimate the Institute carries in the… |
| Maridebart cafraglutide in obesity and overweight in adults: effect on the anchor outcome | Synthesis | Low certainty evidence from 2 contributing trials bears on the effect of Maridebart cafraglutide on the anchor outcome for obesity and overweight in adults. The estimate the Institute carries in the… |
| Petrelintide in obesity and overweight in adults: effect on the anchor outcome | Synthesis | Low certainty evidence from 2 contributing trials bears on the effect of Petrelintide on the anchor outcome for obesity and overweight in adults. The estimate the Institute carries in the monograph… |
| Thymosin beta-4 in cutaneous wound healing and tissue repair: tolerability and discontinuation | Synthesis | Low certainty evidence from 3 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than in… |
| CJC-1295 in growth hormone deficiency and growth-hormone secretagogue pharmacology: tolerability and… | Synthesis | Low certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than in… |
| GHK-Cu in cutaneous wound healing and tissue repair: tolerability and discontinuation | Synthesis | Low certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than in… |
| Maridebart cafraglutide in obesity and overweight in adults: tolerability and discontinuation | Synthesis | Low certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than in… |
| Petrelintide in obesity and overweight in adults: tolerability and discontinuation | Synthesis | Low certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than in… |
| Thymosin beta-4 in cutaneous wound healing and tissue repair: durability of effect | Synthesis | Low certainty evidence bears on whether the effect of Thymosin beta-4 in cutaneous wound healing and tissue repair is maintained across the randomised period. The contributing trials range in… |
| CJC-1295 in growth hormone deficiency and growth-hormone secretagogue pharmacology: durability of effect | Synthesis | Low certainty evidence bears on whether the effect of CJC-1295 in growth hormone deficiency and growth-hormone secretagogue pharmacology is maintained across the randomised period. The contributing… |
page 2 of 2